期刊文献+

炎性乳腺癌诊断和治疗的研究进展 被引量:5

Advances in diagnosis and treatment of inflammatory breast cancer
原文传递
导出
摘要 目前炎性乳腺癌的综合治疗方法已被广泛认可,但国内对该病的诊断和治疗方案尚缺乏统一认识。新辅助化疗、手术加术后化疗或放疗以及分子靶向治疗等治疗方法使炎性乳腺癌患者的总生存率有所提高。笔者就炎性乳腺癌诊断和治疗的新进展作一综述。 Nowadays, the comprehensive treatment for inflammatory breast cancer has been widely accepted, but there is still a lack of general agreement on the diagnostic and treatment criterion for this disease in our country. Some improvements in the overall survival of this disease are achieved by treatments such as neoadjuvant chemotherapy, surgery, and postoperative chemotherapy or radiotherapy as well as molecularly targeted therapy. This paper addresses the recent progress in diagnosis and treatment of inflammatory breast cancer.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第11期1424-1428,共5页 China Journal of General Surgery
关键词 炎性 诊断 乳腺肿瘤 炎性 治疗 综述文献 Breast Neoplasms, Inflammatory/diag Breast Neoplasms, Inflammatory/therapy Review
  • 相关文献

参考文献27

  • 1Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute[J]. J Nail Cancer Inst, 2005, 97(13):966-975.
  • 2Anderson WF, Schairer C, Chen BE, et al. Epidemiology ofinflammatory breast cancer (IBC)[J]. Breast Dis, 2005, 22:9-23.
  • 3Kusama M. A case of secondary inflammatory breast cancer wltla multiple metastases in which operation was possible through letrozole monotherapy[J]. Gan To Kagaku Ryoho, 2011, 38(3):419-.
  • 4Dawood S, Merajver SD, iens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment[J]. Ann Oncol, 2011, 22(3):515-523.
  • 5吕亚萍,杨兴华,毛勤香,孙嗣麒,黄海燕,涂颖华.炎性乳腺癌的X线诊断[J].实用医学杂志,2009,25(16):2721-2722. 被引量:5
  • 6Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer:the disease, the biology, the treatment[J]. CA Cancer J Clin, 2010, 60(6):351-375.
  • 7Yu YH, Wei W, Liu JL. Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis[J]. BMC Cancer, 2012, 12:41.
  • 8邱云峰,党玉林,宋兆东.炎性乳腺癌[J].中国普通外科杂志,1999,8(5):331-332. 被引量:6
  • 9Klein RL, Brown AR, Gomez-Castro CM, et al. Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review[J]. J Cancer, 2010, 1:27-31.
  • 10汪令成,王玉明,高迎飞,师贞宗.葡萄胎致双侧乳房红肿误诊炎性乳腺癌的临床分析[J].中国普通外科杂志,2011,20(11):1278-1279. 被引量:1

二级参考文献8

  • 1Colozza M, Coil S, Moscoiri A M, et al. Induction chemotherapy with eisplatin, doxorubicin, and cyclophospamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer: long-term reslts [J]. Am J Clin Oncol, 1996,19 (1):10-17.
  • 2Bonnier P. Inflammatory carcinomas of the breast: a clincal, pathological, or a clinical and pathological definition [J]. Cancer, 1995,62 : 382-385.
  • 3Walshe JM, Swain SM. Clinical aspects of inflammatol7 breast cancer[J]. Breast Dis, 2005 -2006, 22:35 -44.
  • 4曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2004.2170-2172.
  • 5侯进琳,万希润,向阳,戚庆伟,杨秀玉.葡萄胎临床表现的新特点:113例葡萄胎临床分析[J].生殖医学杂志,2007,16(6):404-408. 被引量:15
  • 6沈坤炜.炎性乳腺癌[J].实用癌症杂志,1998,13(2):158-160. 被引量:13
  • 7徐向红,张晓,王海彦.炎性乳腺癌的临床及影像学特征[J].临床放射学杂志,2009,28(12):1615-1617. 被引量:4
  • 8温珍平,冯铁虹,王磊,刘利.炎性乳腺癌——附6例报告[J].罕少疾病杂志,2004,11(2):5-6. 被引量:3

共引文献9

同被引文献61

  • 1Li BD, Sicard MA, Ampil F, et al. Trimodal thera py for inflammatory breast cancer: a surgeon's perspective [J]. Oncology, 2010,79 ( 1/2 ) : 3-12.
  • 2Dawood S. Biology and management of inflammatory breast cancer [J]. Expert Rev Anticancer Ther, 2010,10(2) :209-220.
  • 3Arias-Pulido H, Chaher N, Gong Y, et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer[J]. BMC Cancer,2012,12:298.
  • 4Kashiwagi S, Yashiro M, Takashima T,et al. Significance of E-cadherin expression in triple-negative breast cancer [J]. Br J Cancer, 2010,103 (2) : 249-255.
  • 5Lan C, Liu JM, Liu TW,et al. Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in analysis [J]. Am J Clin Pathol, 2005,124( 1 ) :97-102.
  • 6Gong Y. Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype [J]. Semin Oncol, 2008,35 ( 1 ) : 33-40.
  • 7Ben Hamida A, Labidi IS, Mrad K,et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin [ J ]. BMC Cancer, 2008,8 : 28.
  • 8Levine PH, Portera CC, Hoffman H J, et al. Evaluation oflymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer[J]. Clin Breast Cancer, 2012,12(4) :232-239.
  • 9yon Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast[ J ]. Breast Cancer Res, 2008,10(2) :R30.
  • 10Aomatsu S, Abigail S, Kelly K, et al. Neoadjuvant systemic treatment of breast cancer [ J ]. J Surg Oncol, 2011,103 (4):348- 357.

引证文献5

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部